Atropine Auto-Injectors (0.5 mg, 1 mg, and 2 mg)

This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT under the authority of FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.

The Office of the Administration for Strategic Preparedness and Response (ASPR), Center for the Strategic National Stockpile (SNS) intends to award a sole source firm fixed price contract to:

Manufacturer Name

Rafa Laboratories LTD

Jerusalem, Israel 97770

The purpose of this acquisition is to provide the United States Government (USG) with pharmaceutical required to support the SNS/CHEMPACK mission. Atropine auto-injectors (0.5 mg, 1 mg, and 2 mg) are essential for future readiness and response to nerve agent or organophosphate poisoning. For emergencies like chemical attacks or accidental exposures, immediate treatment is vital, emphasizing the need for readily available auto-injectors to enable swift response by emergency personnel.

The USG has a need to procure Atropine auto-injectors (0.5 mg, 1 mg, and 2 mg), a U.S. Food and Drug Administration (FDA)-approved and FDA-approved Emergency Use Authorization (EUA) and commercial pharmaceutical, to be utilized during national emergencies and staged in CHEMPACK forward deployed operations at the local level. The USG intends to procure the following: Base Year Ordering Period (1): 2025 - 394,050 EA auto injectors (187,250 ea. of 0.5 mg, 172,800 ea. of 1 mg, and 34,000 ea. of 2 mg)

Optional Ordering Period Year (2): 2026 - 212,000 EA auto injectors (72,000 ea. of 0.5 mg, 72,000 ea. of 1 mg, and 68,000 ea. of 2 mg)

Optional Ordering Period Year (3): 2027 - 212,000 EA auto injectors (72,000 ea. of 0.5 mg, 72,000 ea. of 1 mg, and 68,000 ea. of 2 mg)

Rafa Laboratories is currently the sole manufacturer of Atropine auto-injectors (0.5 mg, 1 mg, and 2 mg). They have no relationships with resellers or distributors for this product.

This notice is for informational and planning purposes and does not constitute a solicitation. This notice of intent is NOT a request for competitive proposals. A determination by the Government not to compete this procurement based upon response(s) to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement must submit in writing their name, address, telephone number, email, UEI/CAGE code, business size, National Drug Code (NDC), and a statement of capability demonstrating their abilities to meet this requirement. The Government will not be responsible for any costs incurred in responding to this notice. All responses must be received by September 03, 2025, at 12:00 PM Eastern Standard Time. All responses must be in writing and must be sent via email to OSContracting.hhs.gov. Reference Atropine Auto-Injectors (0.5 mg, 1 mg, and 2 mg) Acquisition in the subject line. No other submissions will be accepted.